CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.…
CDT Commences Human Skin Studies with QIMA Life Sciences on Novel Tapinarof Combinations in Vitiligo
CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset
CDT Equity (NASDAQ: CDT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 0.2300 USD on 20 November 2026, down 100.0% over 52 weeks. Its 52-week range is 0.2230 USD to 355000.00 USD: the price is 100.0% below the high and 3.1% above the low.
Its market capitalisation is 437.03K USD.
CDT Equity reports an operating margin of 0.0%.
Its debt exceeds its cash by 435.00K USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.